Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma

European Journal of Cancer（2022）

引用 0|浏览2

暂无评分

摘要

•β-blockers have no independent prognostic effect on recurrence-free survival in resected melanoma.•However, β-blockers may prolong recurrence-free survival when combined with adjuvant pembrolizumab.•Our results warrant further investigation of β-blockers combined with immunotherapy.

查看译文

关键词

Melanoma,Immunotherapy,Beta-blockers,Immunomodulation,Adrenergic beta-antagonists

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要